The global heart valve devices market is experiencing substantial growth, driven by the increasing prevalence of valvular heart diseases, such as aortic stenosis and mitral regurgitation, particularly among the aging population. Technological advancements in transcatheter heart valve replacement (TAVR) and repair procedures have revolutionized the treatment landscape, offering minimally invasive alternatives to traditional open-heart surgeries, thus reducing recovery times and improving patient outcomes. Rising awareness of early diagnosis and treatment, coupled with favorable reimbursement policies, is further accelerating market growth. In addition, ongoing research and development efforts by leading companies like Medtronic, Edwards Lifesciences, and Abbott are fostering innovation in both mechanical and tissue heart valves, enhancing device durability and functionality.
Global Heart Valve Devices Market is valued at 9.81 billion in 2022 and is expected to reach USD 23.66 billion by 2030, with a growing CAGR of 13.4% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-heart-valve-devices-market
Below are the Top Heart Valve Devices Companies with a Significant Market Share:
|
Rank |
Company |
Overview |
Product Portfolio |
Sales Geographical Coverage |
Developments |
|
1. |
Medtronic |
|
|
America, Africa, Asia-Pacific, and Europe |
In April 2021, Medtronic announced that it had received FDA device designation status for Emprint Ablation Catheter Kit. The kit is intended to be used with a microwave and lung navigation platform to minimize invasion. This will help the company in gaining the market in the coming years. |
|
2. |
Edwards Lifesciences Corporation |
|
|
America, Africa, Asia-Pacific, and Europe |
In September 2022, Edwards Lifesciences Corporation announced that the PASCAL Precision transcatheter valve repair system has received FDA approval, which is used to treat patients with degenerative mitral regurgitation (DMR). The PASCAL Precision system have its independent grasping, atraumatic clasp and closure, and ability to elongate, enables safe and effective treatment for patients with DMR. This has helped the company to expand its business. |
|
3. |
Abbott |
|
|
America, Africa, Asia-Pacific, and Europe |
In September 2022, Abbott released data from five late-stage presentations showing the benefits of its minimally invasive devices in treating people with various structural heart diseases. The data includes findings that support the value of MitraClip™. It is the world's first and leading transcatheter edge-to-edge repair (TEER) to treat leaky valves in people with mitral regurgitation (MR). New data on Abbott's structural heart therapies were presented at the Cardiovascular Research Foundation's 34th Annual Transcatheter Cardiovascular Therapy (TCT) Scientific Symposium in Boston. This has helped the company to increase its business position in the market. |
|
4. |
Boston Scientific Corporation or its affiliates |
|
|
America, Africa, Asia-Pacific, and Europe |
In September 2020, Boston Scientific Corporation announced that it had introduced a controlled launch of the ACURATE neo2 aortic valve system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with multiple features to improve the clinical performance of the original ACURATE new platform. Compared to the previous generation, the ACURATE neo2 valve system has an expanded indication for patients with aortic stenosis. This has helped the company to gain its product portfolio. |
|
5. |
Artivion, Inc |
|
|
Americas, Africa, Asia-Pacific, and Europe |
In April 2024, Artivion, Inc. presented five-year real-world safety and efficacy data from its On-X Aortic Heart Valve Low INR post-market study at the 104th American Association for Thoracic Surgery Annual Meeting. The findings demonstrated a significantly lower composite primary endpoint of thromboembolism, valve thrombosis, and major bleeding, with an 87% reduction in major bleeding events compared to standard-dose warfarin therapy. |
Conclusion
The global heart valve devices market is poised for continued expansion, fueled by the rising incidence of valvular heart diseases and the growing demand for minimally invasive treatment options. Innovations in transcatheter heart valve technologies and the increasing preference for procedures like TAVR have significantly improved patient outcomes, making these devices more accessible and effective. While high costs and regulatory challenges may hinder rapid adoption in some regions, the market's potential remains strong due to advancements in device durability and performance, supported by key players like Medtronic, Edwards Lifesciences, and Abbott. Furthermore, the growing healthcare infrastructure in emerging markets and increased awareness of early cardiac interventions present promising opportunities for sustained growth.
